EUVIMEDEUVIMED entdecken
Crossref

THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL--GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS

Dewi Wara Shinta, Junaidi Khotib, Eddy Rahardjo, Mahardian Rahmadi, Budi Suprapti

Folia Medica Indonesiana · 2016

DOI: 10.20473/fmi.v51i4.2852 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Folia Medica Indonesiana, 2016. Verfasst von Dewi Wara Shinta und 4 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hydroxyethyl Starch (HES) is a compound that improves intravascular volume effectively and rapidly without causing tissue edema. However, HES also has renal safety profile which is still being debated. Based on clinical experience in Dr. Soetomo Hospital, the frequency of acute renal failure following HES 200/0.5 administration at a dose of less than 20 ml/kg (maximum dose) is very rare. The purpose of this study was to evaluate the effect of HES 200/0.5 at a dose of less than 20 ml/kg in patients undergoing surgery. N-acetyl-b-D-Glucosaminidase (NAG) per urine creatinine ratio and creatinine serum were used as main parameter to assess renal injury. This research was observational and prospective design in patients undergoing elective surgery at Gedung Bedah Pusat Terpadu, Dr. Soetomo Hospital, who requiring resuscitation therapy with HES 200/0.5 and met the inclusion and exclusion criteria. NAG was measured prior to surgery and 12 hours after administration of fluid therapy, while creatinine serum was observed before surgery and 48 hours after resuscitation. This study was conducted for three months, and obtained 50 subjects divided into 2 groups, crystalloid group and HES 200/0.5 group. Demographic and baseline characteristics did not differ between groups, except the total bleeding volume. Total bleeding in HES 200/0.5group was higher than crystalloid group (p

Zitieren

APA

Shinta, D. W., Khotib, J., Rahardjo, E., Rahmadi, M., & Suprapti, B. (2016). THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL--GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS. Folia Medica Indonesiana. https://doi.org/10.20473/fmi.v51i4.2852

Vancouver

Shinta DW, Khotib J, Rahardjo E, Rahmadi M, Suprapti B. THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL--GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS. Folia Medica Indonesiana. 2016. doi:10.20473/fmi.v51i4.2852

BibTeX
@article{Shinta2016,
  author = {Shinta, Dewi Wara and Khotib, Junaidi and Rahardjo, Eddy and Rahmadi, Mahardian and Suprapti, Budi},
  title = {THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL--GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS},
  journal = {Folia Medica Indonesiana},
  year = {2016},
  doi = {10.20473/fmi.v51i4.2852}
}
Kostenlos starten →